Stephen Liu
Georgetown University Hospital Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stephen Liu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02454842 · Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) PatientsRain Oncology Inc · terminated · Non-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC · principal investigator
- Ph2NCT02449681 · Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or SkinRain Oncology Inc · terminated · Metastatic Head-and-neck Squamous-cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:24 UTC. The ranking covers the 200 most relevant of 65 PubMed records, and a shared surname and initials can bring in a namesake. All 65 on PubMed
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).Cancer Discov · 2017651 citationsRCR 20.2
- The BATTLE trial: personalizing therapy for lung cancer.Cancer Discov · 2011649 citationsRCR 13.9
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.Lancet Oncol · 2021365 citationsRCR 19.2
- 228 citationsRCR 11.8
- 170 citationsRCR 10.9
- Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.N Engl J Med · 2025122 citationsRCR 24.2
- A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.Cancer Discov · 2019100 citationsRCR 3.0
- Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.JAMA Oncol · 202490 citationsRCR 9.0
- Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.J Thorac Oncol · 201986 citationsRCR 2.7
- Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.Signal Transduct Target Ther · 202379 citationsRCR 6.1